In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins by Martínez Martínez, Luis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1996, p. 342–348 Vol. 40, No. 2
0066-4804/96/$04.0010
Copyright q 1996, American Society for Microbiology
In Vivo Selection of Porin-Deficient Mutants of Klebsiella
pneumoniae with Increased Resistance to Cefoxitin
and Expanded-Spectrum Cephalosporins
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Four Klebsiella pneumoniae isolates (LB1, LB2, LB3, and LB4) with increased antimicrobial resistance were
obtained from the same patient. The four isolates were indistinguishable in biotype, plasmid content, lipo-
polysaccharide, and DNA analysis by pulse-field gel electrophoresis. Isolate LB1 made TEM-1 and SHV-1
b-lactamases. Isolates LB2, LB3, and LB4 produced SHV-5 in addition to TEM-1 and SHV-1. MICs of
cefoxitin, ceftazidime, and cefotaxime against LB1 were 4, 1, and 0.06 mg/ml, respectively. MICs of ceftazidime
against K. pneumoniae LB2, LB3, and LB4 were >256 mg/ml, and those of cefotaxime were 2, 4, and 64 mg/ml,
respectively. MICs of cefoxitin against K. pneumoniae LB2 and LB3 were 4 mg/ml, but that against K.
pneumoniae LB4 was 128 mg/ml. K. pneumoniae LB4 could transfer resistance to ceftazidime and cefotaxime,
but not that to cefoxitin, to Escherichia coli. Isolate LB4 and cefoxitin-resistant laboratory mutants lacked an
outer membrane protein of about 35 kDa whose molecular mass, mode of isolation, resistance to proteases, and
reaction with a porin-specific antiserum suggested that it was a porin. MICs of cefoxitin and cefotaxime
reverted to 4 and 2 mg/ml, respectively, when isolate LB4 was transformed with a gene coding for the K.
pneumoniae porin OmpK36. We conclude that the increased resistance to cefoxitin and expanded-spectrum
cephalosporins of isolate LB4 was due to loss of a porin channel for antibiotic uptake.
Klebsiella pneumoniae is an important human pathogen (5,
20). Cephalothin- and gentamicin-resistant strains have been
responsible for nosocomial outbreaks during the 1970s (38);
outbreaks caused by strains producing extended-spectrum
b-lactamases (ESBL) have been described since the 1980s (16,
27, 33, 37). In most cases, ESBL are plasmid-mediated en-
zymes providing resistance to oxyiminocephalosporins (cefo-
taxime, ceftazidime, and ceftriaxone, etc.) and to aztreonam.
Less often, other enzymes (MIR-1, CMY-1, FOX-1, and
LAT-1, etc.), degrading a-methoxycephalosporins (cefoxitin
and cefotetan, etc.) as well as oxyimino-b-lactams, have also
been described (15). A recent study on the susceptibilities of
ESBL-producing K. pneumoniae strains has shown that about
25% of them are resistant to cefoxitin (27), but the actual
mechanism of this resistance has not been precisely defined.
Porin loss as a cause of antimicrobial resistance has been
shown in both laboratory mutants and clinical isolates (29).
Two major porins, OmpF and OmpC, have been described for
Escherichia coli. Although OmpC and OmpF porin homologs
have been described for other members of the family Entero-
bacteriaceae (18), the lack of a good definition of K. pneu-
moniae porins has resulted in their having an inferred, rather
than demonstrated, role in antimicrobial resistance in this spe-
cies (11, 31, 40, 47). Besides the phosphate starvation-inducible
PhoE porin (48) and the LamB maltoporin (50), two nonspe-
cific pore proteins (porins), named 37kD and 39-40kD, have
been characterized by their molecular masses and pore sizes in
Enterobacter cloacae strains (19) that were later reidentified as
K. pneumoniae (41). More recently, we have described the
existence of two K. pneumoniae porins called OmpK36 and
OmpK35 (1, 13). While characterization of OmpK35 is still in
progress, the OmpK36 porin, a homolog of the E. coli OmpC
porin, has been characterized in greater detail, and both the
ompK36 nucleotide sequence and a three-dimensional model
are available (2).
While monitoring an outbreak of K. pneumoniae producing
SHV-5 b-lactamase, we noted several isolates that were resis-
tant to cefoxitin, which is not a good substrate for this enzyme.
This study was undertaken to analyze the mechanism of resis-
tance of four isolates, obtained from the same patient, that
showed increasing resistance to b-lactams and to evaluate the
role of outer membrane porin alterations.
(Part of this work was presented at the 34th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Or-
lando, Fla., 1994 [22].)
MATERIALS AND METHODS
Bacterial strains. K. pneumoniae LB1, LB2, LB3, and LB4 were obtained from
the sputum of a patient with pneumonia at Massachusetts General Hospital
(Boston, Mass.). Organisms were identified by standard biochemical methods
and with Pasco panels (Difco, Detroit, Mich.) according to the manufacturer’s
instructions. Isolates LB1, LB2, LB3, and LB4 were obtained from the same
patient. The patient had been treated previously with gentamicin, and amikacin,
cefotetan, and ciprofloxacin but not with oxyimino-b-lactams.
Cefoxitin-resistant mutants derived from isolates LB1, LB2, and LB3 were
obtained on gradient plates containing cefoxitin, as previously described (43). E.
coli J53-2 (F2 met pro Rifr) (6) was used as the recipient strain in conjugation
experiments to study plasmid-transferable b-lactamases. E. coli DH5a (Life
Technologies Inc.) was used to maintain genetically engineered plasmids origi-
nated during this study. K. pneumoniae C3 (44) has been used previously for
porin studies in K. pneumoniae. It was isolated from sewage. It produces both
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OmpK35 and OmpK36. K. pneumoniae 96D is a previously described clinical
isolate (32) producing the AmpC-type cefoxitin-degrading b-lactamase MIR-1.
Strains were stored at 2708C in tryptic soy broth containing 10% glycerol.
Susceptibility testing. MICs of antimicrobial agents were determined by mi-
crodilution according to the guidelines of the National Committee for Clinical
Laboratory Standards with cation-adjusted Mueller-Hinton broth (Ca-MHB)
(Difco). MICs were also determined in L broth (Bacto Tryptone, 10 g; yeast
extract, 5 g; sodium chloride, 5 g; NaOH, 1 mM) plus glucose (2.5 g/liter) (LBG
medium) or in nutrient broth (NB) (Difco). MICs of K. pneumoniae KT5005 and
KT5007 (see below) were determined in MHB supplemented with 30 mg of
potassium tellurite per ml to maintain the plasmids they contain. For three
cefoxitin-resistant mutants, LB2-FOX12, LB2-FOX32, and LB2-FOX64 (see
below), the MICs of cefoxitin were determined on Mueller-Hinton agar with
E-test strips (AB Biodisk, Solna, Sweden).
Typing methods. Biotypes were determined with Pasco panels (type 4G;
Difco) according to the manufacturer’s instructions. Pulsed-field gel electro-
phoresis of genomic DNAs from isolates LB1, LB2, LB3, and LB4 digested with
XbaI was performed by F. Tenover (Centers for Disease Control) (23). Analysis
of plasmid DNAs carried by isolates LB1, LB2, LB3, and LB4 was performed by
0.5% agarose gel electrophoresis (39) except that K. pneumoniae strains were
grown in the presence of 0.5 mM bismuth nitrate–2.5 mM sodium salicylate to
reduce capsule synthesis (9).
Mating and curing experiments. Transfer of resistance from K. pneumoniae
isolates LB1, LB2, LB3, and LB4 to E. coli J53-2 was obtained by mating
experiments (34). Ceftazidime (10 mg/ml), cefoxitin (10 mg/ml), amikacin (10
mg/ml), or gentamicin (10 mg/ml) was used as the selecting agent. For curing
experiments, K. pneumoniae LB2, LB3, and LB4 were cultured on tryptic soy
broth (Difco) at 428C with or without 25 mg of ethidium bromide (Sigma, St.
Louis, Mo.) per ml. Tubes were subcultured daily in the same medium for up to
10 days and plated on tryptic soy agar. After a 24-h incubation period, derivatives
susceptible to ceftazidime or cefoxitin were selected by replica plating.
b-Lactamase characterization. K. pneumoniae LB1, LB2, LB3, and LB4 were
cultured on LBG. Cells were disrupted by sonication, and after removal of
unbroken cells and cell walls by centrifugation, the supernatant fluids were
analyzed for b-lactamase by isoelectric focusing (24). pIs were determined by
using a set of different b-lactamases with known pIs. b-Lactamase activity was
revealed with nitrocefin (0.5 mg/ml). The supernatant fluids used for isoelectro-
focusing were also used to evaluate their abilities to break down cefazolin,
ceftazidime, cefotaxime, aztreonam, cefoxitin, and imipenem. Antimicrobial pa-
per disks were impregnated with supernatant fluids from the different isolates,
and the inhibition zones produced by them and by nonimpregnated disks against
E. coli J53-2 were compared. A reduction of the zone of the activity with the
impregnated disk was considered evidence for b-lactamase activity against the
corresponding antimicrobial agent.
Isolation and analysis of outer membrane components. Cell envelopes (cyto-
plasmic and outer membranes) were isolated from K. pneumoniae strains grown
in LBG, NB, and Ca-MHB medium by centrifugation at 100,000 3 g for 1 h at
48C after French press cell lysis. Outer membrane proteins (OMP) were isolated
as sodium lauryl sarcosynate-insoluble material (10, 44). Isolation of the 35-kDa
OMP from strain LB1 was performed by a combination of two methods for porin
isolation (28, 30), as described for the isolation of OmpK36 porin (1). Lipopoly-
saccharide (LPS) was purified by the phenol-water method (51) or obtained from
proteinase K-treated cell lysates (12).
Electrophoretic analysis of OMP by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was performed with 11% acrylamide–0.35% bisac-
rylamide–0.1% SDS by using Laemmli’s buffers (21) and Coomassie blue stain-
ing. Samples were boiled for 5 min in sample buffer before electrophoresis.
Densitometric analysis of OMP separated by SDS-PAGE was carried out with a
Bio Image densitometer and Whole band 3.1 software (Millipore). LPS, either
purified as described above or from proteinase K-treated cell lysates (12), was
analyzed by electrophoresis in 15% polyacrylamide gels and silver staining (46).
Western blot (immunoblot) analysis of SDS-PAGE-separated OMP was carried
out with the buffers and conditions described by Towbin et al. (45), Immobilon
P membranes (Millipore), rabbit antiserum raised against purified OmpK36
porin (2), and alkaline phosphatase-labeled anti-rabbit immunoglobulin G (Sig-
ma). Enzyme was detected with BCIP-NBT (5-bromo-4-chloro-3-indolylphos-
phate toluidinium–nitroblue tetrazolium) (3).
Plasmid construction. Plasmids encoding the complete K. pneumoniae porin
OmpK36 or a truncated version were constructed and tagged with a tellurite
resistance cassette to allow selection of plasmid-containing clones in the mul-
tiresistant background of isolate LB4. The plasmid construction strategy is shown
in Fig. 1. Plasmid pDT1558 (49) was used as source of the tellurite resistance
cassette kilA-Ter, which was cloned into pUC18Not (14), yielding plasmid
pSHA1. The kilA-Ter cassette was then obtained as a NotI-NotI fragment from
pSHA1 and was cloned into the unique NotI site of pSUV7 (2), a pACYC184-
derived plasmid carrying the complete ompK36 gene. The resulting pSHA2
plasmid was introduced into K. pneumoniae LB4, giving strain KT5005. Plasmid-
containing clones were selected with potassium tellurite (30 mg/ml) and chlor-
amphenicol (25 mg/ml). The NruI-XmnI ompK36-containing fragment of pSUV7
was isolated and used to replace the HindII-HindII fragment of plasmid
pACYC184. The resulting pFR165 plasmid contains two HindII sites, located
within the ompK36 gene. Elimination of the intra-ompK36 HindII-HindII frag-
ment of pFR165 gave plasmid pFR167, which was afterwards labeled with
tellurite resistance by cloning the kilA-Ter cassette from pSHA1 into its unique
NotI site. Therefore, the resulting pSHA4 plasmid contains a truncated ompK36
gene (DompK36). Selection of tellurite-resistant LB4 clones containing plasmid
pSHA4 (strain KT5007) was performed as described above. Plasmids were in-
troduced in K. pneumoniae LB4 by transformation or electroporation.
Restriction endonucleases, T4 DNA ligase, and calf intestinal alkaline phos-
phatase were from Pharmacia. Large- and miniscale plasmid isolation were
carried out by alkaline lysis (8). DNA procedures for agarose gel electrophoresis,
plasmid transformation, and recovery of DNA fragment from gels were standard
(39).
RESULTS
Typing methods. K. pneumoniae isolates LB2, LB3, and LB4
were indistinguishable in biotype: 777 727 711. Isolate LB1
differed slightly (777 727 311) because of its cephalothin sus-
ceptibility. Analysis of plasmid and total DNAs gave identical
results for all four isolates: each carried four plasmids of about
180, 120, 3.9, and 3.1 kb (Fig. 2A), and the same pulsed-field
gel electrophoresis patterns were obtained (Fig. 2B). Identical
LPS profiles were also observed for isolates LB1, LB2, LB3,
and LB4 after electrophoretic and silver staining analysis of
both isolated LPSs and proteinase K-treated whole cells (data
not shown). Electrophoretic profiles consisted of high-molec-
ular-weight LPS (O-antigen-enriched molecules) and low-mo-
lecular-weight LPS (core-enriched molecules).
Susceptibility testing. Table 1 shows that isolate LB1 was
susceptible to both expanded-spectrum cephalosporins and ce-
foxitin, isolates LB2 and LB3 were resistant to expanded-spec-
trum cephalosporins but susceptible to cefoxitin, and isolate
LB4 was resistant to both expanded-spectrum cephalosporins
and cefoxitin. All isolates were susceptible to imipenem and
resistant to tetracycline. K. pneumoniae LB1 was susceptible to
amikacin; isolates LB2, LB3, and LB4 were not. Isolates LB1,
LB2, and LB4 were resistant to gentamicin and chloramphen-
icol, but isolate LB3 was susceptible to both agents. Although
all four isolates were susceptible to ciprofloxacin, isolate LB4
was twice less susceptible than isolates LB1, LB2, and LB3.
Variations between MICs obtained in LBG and NB media
were within one twofold dilution, except for aminoglycosides,
whose MICs were four- to eightfold lower in NB than in Ca-
MHB medium. MICs of cefoxitin for mutants LB2-FOX12,
LB2-FOX32, and LB2-FOX64, were 12, 32, and 64 mg/ml,
respectively, as determined by the E-test. MICs of cefoxitin for
mutants LB1-FOX256, LB2- FOX256, and LB3-FOX256 were
.256 mg/ml.
Mating and curing experiments. The 120-kb plasmid cod-
ed for resistance to expanded-spectrum cephalosporins and
amikacin, and the 180-kb plasmid coded for resistance to
gentamicin and chloramphenicol, as shown by conjugation ex-
periments. Cefoxitin resistance could not be transferred by
conjugation from K. pneumoniae LB4 to E. coli J53-2. Cefta-
zidime-susceptible mutants were obtained from isolates LB2,
LB3, and LB4. They also became susceptible to aztreonam
(and to amikacin) and had increased susceptibility to cefo-
taxime, but plasmid analysis for these mutants still revealed the
presence of the 120-kb plasmid (data not shown); mutants
derived from LB2 and LB3 were susceptible to cefoxitin, but
mutants derived from LB4 still were resistant to cefoxitin
(MIC, 128 mg/ml). Cefoxitin-susceptible mutants could not be
obtained from isolate LB4.
b-Lactamase characterization. K. pneumoniae LB1 pro-
duced TEM-1 (pI, 5.4) and SHV-1 (pI, 7.6). Isolates LB2, LB3,
and LB4 produced SHV-5 (pI 8.2) in addition to TEM-1 and
SHV-1. Supernatants containing crude b-lactamases from
LB1, LB2, LB3, and LB4 did not affect inhibition zones of E.
coli J53-2 around cefoxitin (or imipenem) disks. The superna-
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tants from LB2, LB3, and LB4 antagonized the activities of
disks of cefazolin, ceftazidime, cefotaxime, and aztreonam.
OMP characterization. SDS-PAGE analysis (Fig. 3) of the
OMP of K. pneumoniae isolates grown in LBG or NB medium
(high- and low-osmolarity media, respectively) showed only
two major proteins, of about 32 and 35 kDa, in the 29- to
45-kDa range for isolates LB1, LB2, and LB3. The 35-kDa
OMP was absent in isolate LB4 and the ceftzidime-susceptible
mutants derived from it. Mutants LB2-FOX12 and LB2-
FOX32 also produced the 32- and 35-kDa OMP (not shown).
Mutant LB2-FOX64 produced only the 32-kDa OMP (Fig. 3,
lane 5). Therefore, mutants with high levels of resistance to
cefoxitin, such as LB2-FOX64 (MIC, 64 mg/ml) and LB1-
FOX256, LB2-FOX256, and LB3-FOX256 (MICs, .256 mg/
ml), do not express the 35-kDa porin, whereas mutants with
cefoxitin MICs of up to 32 mg/ml still express variable amounts
of the 35-kDa OMP. Densitometric analysis of SDS-PAGE-
separated OMP revealed that the ratio between the 32- and
35-kDa bands decreased by 22 to 35% in isolates LB2 and LB3
compared with isolate LB1. The same OMP electrophoretic
pattern was observed when isolates were grown in the Ca-
MHB medium used for MIC determinations. As controls, K.
pneumoniae 96D (not shown) and C3 showed the 32- and
35-kDa OMP and an additional OMP of about 36 kDa (the
OmpK36 porin) when grown in L broth (Fig. 3).
The porin nature of the 35-kDa OMP present in isolates
LB1, LB2, and LB3 and absent from isolate LB4 (and from
cefoxitin-resistant mutants derived from the first three isolates)
was studied (Fig. 4). The outer membrane of LB1 was isolated
and subjected to a combination of two typical methods for the
isolation of porins based on their trypsin resistance and strong
noncovalent association with the peptidoglycan. The pepti-
doglycan-associated, trypsin-resistant material of isolate LB1
was separated by gel permeation chromatography into three
peaks (Fig. 4A). SDS-PAGE and Coomassie blue staining (Fig.
4B) of these chromatographic peaks revealed that peak I con-
FIG. 1. Construction of plasmids containing the porin-coding ompK36 gene selectable in the multiresistant K. pneumoniae LB4 background. Plasmid pSUV7
contains the entire ompK36 gene. pSUV7 was modified by cloning the kilA-Ter cassette, which confers resistance to potassium tellurite. The resulting pSHA2 plasmid
confers an OmpK361 phenotype after introduction into K. pneumoniae LB4. As a control, plasmid pSHA4, which contains kilA-Ter for selection and a HindII-HindII
intra-ompK36 deletion, was used.
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tained only the 35-kDa OMP from isolate LB1, whereas peaks
II and III did not contain detectable proteins. Further analysis
by SDS-PAGE and silver staining for LPS (Fig. 4C) demon-
strated that the 35-kDa OMP isolated in peak I was free of
LPS detectable by this sensitive type of analysis, whereas peaks
II and III contained, respectively, high-molecular-mass LPS
(and some low-molecular-mass LPS) and low-molecular-mass
LPS.
The results described above strongly suggested a porin na-
ture for this protein. This was confirmed by the results shown
in Fig. 5. When isolate LB4 was transformed with plasmid
pSHA2, carrying the complete gene coding for the OmpK36
porin, an additional OMP, with an Mr coinciding with that of
OmpK36, was observed in its outer membrane (Fig. 5A), while,
as expected, LB4 transformed with a plasmid containing a
truncated ompK36 gene did not show any OMP of 35 to 36
kDa. Western blot analysis with antiserum against the OmpK36
porin (Fig. 5B) confirmed that the 35-kDa OMP from LB1 and
the 36-kDa OMP expressed by LB4 transformed with the
ompK36-carrying plasmid are recognized by the anti-porin se-
rum. Minor nonspecific reactions could be seen in some cases
(Fig. 5B, lanes 1 and 3 but not lane 4) with the 32-kDa OMP
common to LB1, LB2, LB3, and LB4. However, the specificity
of the detection is shown by the absence of recognition of
the OmpK35 porin of strain C3 (Fig. 5, lanes 6) by the anti-
OmpK36 serum.
Finally, the porin nature of the 35-kDa OMP expressed by
isolates LB1, LB2, and LB3 can be deduced from the fact that
isolate LB4 transformed with plasmid pSHA2 carrying the
porin-coding gene ompK36 reverted in its antimicrobial sus-
ceptibility levels to those of isolate LB2 (Table 1).
DISCUSSION
There are several reports on the association of loss of porins
and increased resistance to antimicrobial agents, mainly in E.
coli and Salmonella typhimurium (17, 25, 35). For other gram-
negative bacteria the association of loss of OMP in the range
of 30 to 50 kDa and resistance to antimicrobial agents has been
considered evidence of the role of these OMP as porins. How-
ever, in many cases the exact nature of the protein has not been
established, and the assumption that the involved proteins
were porins were largely based on their molecular masses. This
has been the case for several reports concerning K. pneumoniae
(31, 36, 47).
Two nonspecific porin proteins have been described for K.
pneumoniae, named variously 37kD and 39-40kD (19, 41) or
OmpK36 and OmpK35 (2, 13). The three initial clinical iso-
lates of our series, LB1, LB2, and LB3, lacked one of these
porins, but the presence of the 35-kDa one prevented the high
level of resistance to expanded-spectrum cephalosporins and
cefoxitin observed in isolate LB4. In isolate LB4 the absence of
the 35-kDa porin, together with the expression of the SHV-5
enzyme, account for the high level of resistance observed. The
FIG. 2. Plasmid (A) and PFGE (B) patterns of K. pneumoniae LB1 (lanes 1),
LB2 (lanes 2), LB3 (lanes 3), and LB4 (lanes 4). Molecular sizes (in kilobases)
are indicated in the margins.
FIG. 3. SDS-PAGE analysis of OMP from isolates LB1 (lane 1), LB2 (lane
2), LB3 (lane 3), LB4 (lane 4), and LB2-FOX64, a cefoxitin-resistant laboratory
mutant derived from K. pneumoniae LB2 (lane 5). Sizes of molecular mass
markers (in kilodaltons) are indicated on the left. Only the relevant part of the
gel is shown.
TABLE 1. MICS of antimicrobial agents against evaluated strains
Strain
MIC (mg/ml) againsta:
AMP CR FOX CAZ CAZ-CAC AZT CTX CTX-CAC PIM IMP AK G CIP C TE
LB1 .256 2 4 1 #0.125 0.125 0.06 #0.125 0.03 0.25 0.5 16 0.5 .128 64
LB2 .256 128 4 .256 #0.125 .256 2 #0.125 0.5 0.25 32 32 0.5 .128 64
LB3 .256 256 4 .256 #0.125 .256 4 #0.125 1 0.25 32 1 0.5 4 64
LB4 .256 .256 128 .256 8 .256 64 2 .8 0.25 32 32 1 .128 64
KT5005b NDc ND 4 .256 #0.125 ND 2 #0.125 ND ND 8 4 0.5 .128 64
KT5007d ND ND 128 .256 4 ND 64 1 ND ND 8 16 1 .128 64
a AMP, ampicillin; CR, cephalothin; FOX, cefoxitin, CAZ, ceftazidime; CAZ-CAC, ceftazidime plus 2 mg of clavulanic acid per ml; AZT, aztreonam; CTX,
cefotaxime; CTX-CAC, cefotaxime plus 2 mg of clavulanic acid per ml; PIM, cefepime; IMP, imipenem; AK, amikacin, G, gentamicin; CIP, ciprofloxacin; C,
chloramphenicol; TE, tetracycline.
b LB4(pSHA2); expresses OmpK36 porin.
c ND, not determined.
d LB4(pSHA4); porin deficient.
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relationship between the porin deficiency and the resistance
phenotypes is demonstrated in strain KT5005: cloning and
expression of the ompK36 porin-coding gene in K. pneumoniae
LB4 reverted the susceptibility of this strain to that of iso-
late LB2 (Table 1). Inactivation of cefoxitin by our clinical
isolates was not detected. The resistance to this antimicrobial
agent could not be reverted in vitro or transferred to E. coli
by conjugation, therefore suggesting that isolate LB4 has
a nonreversible chromosomal mutation. The resistance of
LB4 and mutants resistant to high cefoxitin concentrations
(MICs . 64 mg/ml) is associated with the loss of the 35-kDa
porin.
Treatment of infections caused by K. pneumoniae strains
producing ESBL is difficult not only because of their resistance
to expanded-spectrum cephalosporins but also because of their
resistance to other antimicrobial agents encoded by the same
or different plasmids. Among b-lactams, cephamycin and imi-
penem seem to be reasonable alternatives, since preliminary
data show that b-lactamases degrading cefoxitin and related
drugs are uncommon, and resistance to imipenem in K. pneu-
moniae has not yet been described.
The results from this study show that cefoxitin may not be
adequate for treatment of K. pneumoniae strains producing
ESBL: mutants selected in vivo that lack porins (LB4, for
instance) are resistant to cefoxitin, and cefoxitin-resistant,
porin-deficient mutants are easily selected in vitro and show
decreased susceptibilities to other b-lactams, including ex-
panded-spectrum cephalosporins. According to National Com-
mittee for Clinical Laboratory Standards breakpoints for re-
sistance, isolates LB2 and LB3 could be considered susceptible
to cefotaxime. Although this is debatable, if the breakpoints
proposed by some committees are considered (4, 26, 42), the
loss of the 35-kDa porin makes K. pneumoniae LB4 a strain
resistant to cefotaxime and other b-lactam antibiotics. The
combination of cefotaxime with clavulanic acid (inhibiting
SHV-5) determines a 32-fold decrease in the MIC of cefo-
taxime against K. pneumoniae LB4, but this combination is not
commercially available and, in spite of this decrease, the MIC
obtained is probably high enough to preclude its use. It could
be interesting to study the activities of new combinations of
expanded-spectrum cephalosporins with b-lactamase inhibi-
tors to evaluate their possible clinical applications against K.
pneumoniae strains producing ESBL. Interestingly, imipenem
uniformly maintained its activity against these porinless mu-
tants. This can be attributed to the small size of the molecule
and its zwitterionic configuration, which facilitate its diffusion
through the outer membrane. From these data, we suggest the
use of imipenem if a b-lactam is considered for the treatment
of infections caused by K. pneumoniae strains producing ESBL,
and we suggest that the usefulness of other carbapenems be
explored.
The susceptibility of isolate LB3 to both gentamicin and
chloramphenicol was unexpected, as it contains the (apparent-
ly) same plasmid of 180 kb observed in isolates LB1, LB2, and
LB4, which are resistant to both agents. New experiments have
been planned to understand the different susceptibility pattern
of isolate LB3.
This study was initially designed to study the mechanisms of
resistance to b-lactam antibiotics. However, we have also
noted that LB4 is slightly (but consistently) more resistant to
ciprofloxacin than isolates LB1, LB2, and LB3 and mutant
KT5005. This suggests that the loss of porins contributes to
resistance to quinolones in K. pneumoniae. A two- to fourfold
increase in MICs of hydrophilic quinolones has been similarly
observed in E. coli mutants lacking OmpF. For our isolates, we
still do not know if the diminished activity of ciprofloxacin is
related to mutations in gyrase-coding genes or if it is due to a
pleiotropic effect of the loss of the 35-kDa porin. Also, the
detection of an operon hybridizing with a mar-specific DNA
probe (7) suggests that mar mutants may (or probably) exist in
K. pneumoniae. New experiments are in progress to evaluate
these mechanisms.
FIG. 4. Isolation of the 35-kDa OMP from isolate LB1. (A) Gel permeation
chromatography on Sephacryl S200 of cell envelopes subjected to a porin isola-
tion method. (B) SDS-PAGE of relevant fractions. Lanes: 1, OMP from K.
pneumoniae LB1; 2, peak I; 3, peak II; 4, peak III. (C). Fractions analyzed for
LPS content. Lanes: 1, LPS from K. pneumoniae LB1; 2, peak I; 3, peak II; 4,
peak III; 5, smooth LPS from an S. typhimurium strain; 6, rough LPS from an S.
typhimurium strain. Sizes of molecular mass markers (in kilodaltons) are indi-
cated on the left of panel B.
FIG. 5. SDS-PAGE (A) and Western blot with anti-OmpK36 serum (B) of
OMP from K. pneumoniae LB1 (lanes 1), the 35-kDa OMP purified from K.
pneumoniae LB1 (lanes 2), OMP from K. pneumoniae LB4 carrying the truncated
ompK36 gene of plasmid pSHA4 (lanes 3), OMP from K. pneumoniae LB4
carrying the ompK36-coding plasmid pSHA2 (lanes 4), purified OmpK36 porin
(lanes 5); and OMP from K. pneumoniae C3 expressing porins OmpK36 (solid
dot) and OmpK35 (empty dot) (lanes 6). Sizes of molecular mass markers (in
kilodaltons) are indicated on the left of panel A. Only the relevant parts of the
gel and Western blot are shown.
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348 MARTÍNEZ-MARTÍNEZ ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on A
ugust 1, 2017 by U
S
E
/B
C
T
A
.G
E
N
 U
N
IV
E
R
S
IT
A
R
IA
http://aac.asm
.org/
D
ow
nloaded from
 
